SLFN11 and hepatocellular carcinoma: Recent studies have strongly suggested that SLFN11 is a key regulator in the immune microenvironment of hepatocellular carcinoma (HCC) and shows great potential as a biomarker for predicting the efficacy of immune checkpoint inhibitors (ICI) treatment.